Latest News
New Jersey | July 10 2026
HEC Pharm has formally entered into an agreement with Accutar, a leading global AI-enabled drug discovery company, to form a new company ("NewCo") and jointly develop an innovative drug pipeline based on Regulated Induced Proximity Targeting Chimera (RIPTAC) technology. The pipeline's lead indication will be metastatic castration-resistant prostate cancer (mCRPC), a disease area with substantial unmet medical need worldwide, limited effective treatment options, and a clear need for new medicines that can improve patients'...
Results from a Phase 1 clinical study of AC699, Accutar Biotechnology’s investigational oral estrogen receptor (ER) degrader, were published in Nature Communications on December 17, 2025. The study assessed safety and preliminary antitumor activity in 37 patients with heavily pretreated ER-positive/HER2-negative advanced or metastatic breast cancer.
All adverse events considered related to AC699 were mild or moderate (Grade 1 or 2), with no dose...
CRANBURY, N.J.--(BUSINESS WIRE)--Accutar Biotechnology, Inc., a biotechnology company focusing on artificial intelligence (AI)-enabled drug discovery, announced today that the US Food and Drug Administration (FDA) has granted the investigation of AC699 a Fast Track designation for the treatment of patients with estrogen receptor (ER)-positive, human epidermal growth factor receptor-2 (HER2)-negative, estrogen receptor 1 (ESR1)-mutated advanced or metastatic breast cancer with disease progression on...
– Differentiated Mechanism of Action of a Chimeric Degrader as Compared to Fulvestrant and Novel SERDs –
– Treatment with AC699 Monotherapy Resulted in 21% ORR for All Evaluable Patients, and 50% for Those Who Had an ESR1 Mutation –
– Favorable Safety and Tolerability Profile at All Doses with No DLTs or ≥ Grade 3 Adverse Events Related to AC699...
Evommune will leverage Accutar's AI-empowered drug discovery platform for therapies targeting chronic inflammatory diseases
PALO ALTO, Calif. and CRANBURY, N.J., Nov. 28, 2023 /PRNewswire/ -- Evommune, Inc., a biotechnology company discovering and developing new ways to treat immune-mediated inflammatory diseases, and Accutar Biotechnology Inc., a company focusing on artificial intelligence (AI)-empowered drug discovery, today announced a new strategic partnership focused on the discovery of novel small molecule...